Friday, June 28, 2019 7:07:48 PM
If someone tries to convince you to buy a stock they usually have a personal agenda to do so. Not because they are concerned about you making money but about convincing you to buy so they can make money. Same is true for those yelling sell.
Recent AFMD News
- Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology • GlobeNewswire Inc. • 04/24/2024 08:05:00 AM
- Affimed Reports 2023 Financial Results and Operational Progress • GlobeNewswire Inc. • 03/28/2024 10:30:00 AM
- Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024 • GlobeNewswire Inc. • 03/21/2024 10:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/11/2024 08:05:48 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/06/2024 11:34:50 AM
- Affimed Announces 1-for-10 Reverse Stock Split • GlobeNewswire Inc. • 03/06/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/08/2024 09:45:56 PM
- Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung Cancer • GlobeNewswire Inc. • 01/08/2024 09:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/08/2024 01:11:55 PM
- Affimed Announces Leadership Change and Organizational Restructuring • GlobeNewswire Inc. • 01/08/2024 01:00:00 PM
- Affimed Announces Sale of Wholly-Owned Subsidiary AbCheck • GlobeNewswire Inc. • 01/03/2024 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/11/2023 11:10:55 AM
- Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer Patients • GlobeNewswire Inc. • 12/11/2023 11:02:00 AM
- Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs) • GlobeNewswire Inc. • 12/11/2023 11:00:00 AM
- Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24 • GlobeNewswire Inc. • 12/04/2023 11:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/30/2023 12:00:57 PM
- Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational Progress • GlobeNewswire Inc. • 11/14/2023 11:30:00 AM
- Affimed Announces Acimtamig as International Nonproprietary Name for AFM13 • GlobeNewswire Inc. • 11/09/2023 11:30:00 AM
- Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023 • GlobeNewswire Inc. • 11/07/2023 11:30:00 AM
- Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer • GlobeNewswire Inc. • 11/03/2023 04:05:00 PM
- Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting • GlobeNewswire Inc. • 11/02/2023 01:05:00 PM
- Affimed to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 11/01/2023 10:30:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 10/04/2023 10:40:55 AM
- Affimed Announces Listing Transfer to Nasdaq Capital Markets • GlobeNewswire Inc. • 10/04/2023 10:30:00 AM
- Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer • GlobeNewswire Inc. • 09/27/2023 01:05:00 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM